c-Mpl acts as a primary regulator of megakaryocytopoiesis and platelet production and is essential for the maintenance of normal hematopoiesis in humans. An impaired posttranslational processing of Mpl with underglycosylation has been proposed as a molecular defect of polycythemia vera (PV) and chronic idiopathic myelofibrosis (

CIMF; Molinterno and Spivak, Blood 1999; 94: 2555
).

To visualize the subcellular localization of megakaryocyte c-Mpl protein in myeloproliferative diseases and myelodysplastic/myeloproliferative disorders we performed an imaging study by confocal laser scanning microscopy. Bone marrow trephines from normal bone marrow donors (n=14), patients with essential thrombocythemia (ET, n=15), PV (n=18), CIMF (n=15), myelodysplastic syndromes (MDS) including refractory anemia with ringed sideroblasts (RS; n=12) and so-called essential thrombocythemia with RS (ET/RS; n=67) were examined. Immunohistochemistry was performed using a rabbit polyclonal antibody recognizing glycosylated and unglycosylated c-Mpl and semiquantitatively evaluated by scoring of plasmalemmal vs. cytoplasmic labeling (score 1–3).

Our results provide evidence that normal megakaryocytes show a pronounced cell surface expression of c-Mpl. In PV and CIMF, c-Mpl suface expression was significantly reduced (p<0.001), while cytoplasmic expression was often strongly accentuated. In ET, heterogeneous patterns of membraneous labeling were observed ranging from normal to decreased. In MDS, plasmalemmal immunoreacativity was generally down-regulated. In ET/RS c-Mpl imaging revealed a heterogeneous positivity with different degrees of plasmalemmal vs. cytoplasmic immunoreactivity in keeping either with CIMF, true ET or MDS.

The role of c-Mpl as a biomarker of Ph-negative MPDs is controversely discussed. A weak megakaryocyte c-Mpl staining which may complement morphologic distinction has been observed in PV (

Tefferi et al., Blood 2000; 96: 771
). Our findings suggest that the strikingly reduced cell surface c-Mpl expression despite equivalent or increased mRNA levels (
Bock et al., J Pathol 2004; 203: 609
) may result in impaired receptor domains for TPO in PV and CIMF and is a characteristic epigenetic abnormality of theses entities. Upon consideration of all our clinico-pathological data, so-called ET/RS is now fracturing in clearly defined haematological diseases which could be categorized as CIMF/RS (38/67), true ET/RS (10/67) or different MDS categories (n=19). The heterogeneous patterns of c-Mpl expression further contribute to define positive criteria for the discrimination of the distinct entities within in the ET/RS group.

Topics:
microscopy, confocal scanning laser, myeloproliferative disease, sideroblast, ringed, thrombocythemia, hemorrhagic, diagnostic imaging, myelodysplastic syndrome, biological markers, complement system proteins, hematological diseases, mpl protein, human

Author notes

Corresponding author

2005, The American Society of Hematology
2004
Sign in via your Institution